CoChat
Sign Up
Cited by 561Renin-Angiotensin System StudiesCoagulation, Bradykinin, Polyphosphates, and AngioedemaEicosanoids and Hypertension Pharmacology

Counter-regulatory renin–angiotensin system in cardiovascular disease

Open access
Paz Ocaranza, Maria, Riquelme, Jaime A., García, Lorena, Jalil, Jorge E., Chiong, Mario, Santos, Robson A. S., Lavandero, Sergio·2020·Nature Reviews Cardiology
DOI 10.1038/s41569-019-0244-8PMC PMC7097090
Open this paper in CoChat — free accountOpen PDF

Abstract

The renin-angiotensin system is an important component of the cardiovascular system. Mounting evidence suggests that the metabolic products of angiotensin I and II - initially thought to be biologically inactive - have key roles in cardiovascular physiology and pathophysiology. This non-canonical axis of the renin-angiotensin system consists of angiotensin 1-7, angiotensin 1-9, angiotensin-converting enzyme 2, the type 2 angiotensin II receptor (AT 2 R), the proto-oncogene Mas receptor and the Mas-related G protein-coupled receptor member D. Each of these components has been shown to counteract the effects of the classical renin-angiotensin system. This counter-regulatory renin-angiotensin system has a central role in the pathogenesis and development of various cardiovascular diseases and, therefore, represents a potential therapeutic target. In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin-angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41569-019-0244-8

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 187

  1. [1]Ferrario CM Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research J. Renin Angiotensin Aldosterone Syst. 2006 7 3 14 17083068
  2. [2]Karnik SS International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected] Pharmacol. Rev. 2015 67 754 819 26315714 PMC4630565
  3. [3]Forrester SJ Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology Physiol. Rev. 2018 98 1627 1738 29873596 PMC6335102
  4. [4]Teixeira LB Ang-(1-7) is an endogenous beta-arrestin-biased agonist of the AT1 receptor with protective action in cardiac hypertrophy Sci. Rep. 2017 7 11903 28928410 PMC5605686
  5. [5]Jesus ICG Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes Am. J. Physiol. Cell. Physiol. 2018 314 C702 C711 29443552
  6. [6]Mendoza-Torres E Protection of the myocardium against ischemia/reperfusion injury by angiotensin-(1-9) through an AT2R and Akt-dependent mechanism Pharmacol. Res. 2018 135 112 121 30048754
  7. [7]Li T Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility Int. J. Cardiol. 2018 264 137 144 29685688 PMC5960429
  8. [8]Yu L Yuan K Phuong HT Park BM Kim SH Angiotensin-(1-5), an active mediator of renin-angiotensin system, stimulates ANP secretion via Mas receptor Peptides 2016 86 33 41 27660028
  9. [9]Chang L Bmal1 in perivascular adipose tissue regulates resting-phase blood pressure through transcriptional regulation of angiotensinogen Circulation 2018 138 67 79 29371216 PMC6030431
  10. [10]Tetzner A G-protein-coupled receptor MrgD is a receptor for angiotensin-(1-7) involving adenylyl cyclase, cAMP, and phosphokinase A Hypertension 2016 68 185 194 27217404
  11. [11]Bosnyak S Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors Clin. Sci. 2011 121 297 303 21542804
  12. [12]Kostenis E G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor Circulation 2005 111 1806 1813 15809376
  13. [13]Gaidarov I Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor Cell. Signal. 2018 50 9 24 29928987
  14. [14]Santos RA Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas Proc. Natl Acad. Sci. USA 2003 100 8258 8263 12829792 PMC166216
  15. [15]Meems LMG Design, synthesis, and actions of an innovative bispecific designer peptide Hypertension 2019 73 900 909 30798663 PMC6512958
  16. [16]Leonhardt J Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS Hypertension 2017 69 1128 1135 28461604
  17. [17]Zhang H Structural basis for selectivity and diversity in angiotensin II receptors Nature 2017 544 327 332 28379944 PMC5525545
  18. [18]Lobo MD Sobotka PA Pathak A Interventional procedures and future drug therapy for hypertension Eur. Heart J. 2017 38 1101 1111 27406184 PMC5400047
  19. [19]Pan X FGF21 Prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice Cell Metab. 2018 27 1323 1337.e5 29706566
  20. [20]Lawson C Vicencio JM Yellon DM Davidson SM Microvesicles and exosomes: new players in metabolic and cardiovascular disease J. Endocrinol. 2016 228 R57 R71 26743452
  21. [21]Yellon DM Davidson SM Exosomes: nanoparticles involved in cardioprotection? Circ. Res. 2014 114 325 332 24436428
  22. [22]Pironti G Circulating exosomes induced by cardiac pressure overload contain functional angiotensin II type 1 receptors Circulation 2015 131 2120 2130 25995315 PMC4470842
  23. [23]Lyu L A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes J. Mol. Cell. Cardiol. 2015 89 268 279 26497614 PMC4988239
  24. [24]Hamming I The emerging role of ACE2 in physiology and disease J. Pathol. 2007 212 1 11 17464936 PMC7167724
  25. [25]Yamazato Y Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer Hypertension 2009 54 365 371 19564552 PMC2732127
  26. [26]Ferreira AJ Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension Am. J. Respir. Crit. Care Med. 2009 179 1048 1054 19246717 PMC2689912
  27. [27]Li G Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase J. Am. Soc. Hypertens. 2017 11 842 852 29146157
  28. [28]Sztuka K Orszulak-Michalak D Jasinska-Stroschein M Systematic review and meta-analysis of interventions tested in animal models of pulmonary hypertension Vasc. Pharmacol. 2018 110 55 63 30145225
  29. [29]Epelman S Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes J. Card. Fail. 2009 15 565 571 19700132 PMC3179261
  30. [30]Shao Z Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure J. Card. Fail. 2013 19 605 610 24054336 PMC3781953
  31. [31]Johnson JA West J Maynard KB Hemnes AR ACE2 improves right ventricular function in a pressure overload model PLOS ONE 2011 6 e20828 21695173 PMC3112229
  32. [32]Rathinasabapathy A rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling Front. Physiol. 2018 9 271 29731719 PMC5922219
  33. [33]Hemnes AR A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Eur. Respir. J. 2018 51 1702638 29903860 PMC6613216
  34. [34]Khan A A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome Crit. Care 2017 21 234 28877748 PMC5588692
  35. [35]Hampl V Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia Physiol. Res. 2015 64 25 38 25194138
  36. [36]Yamada K Iyer SN Chappell MC Ganten D Ferrario CM Converting enzyme determines plasma clearance of angiotensin-(1-7) Hypertension 1998 32 496 502 9740616
  37. [37]Kastin AJ Pan W Concepts for biologically active peptides Curr. Pharm. Des. 2010 16 3390 3400 20726835 PMC3535498
  38. [38]Bennion DM Neuroprotection by post-stroke administration of an oral formulation of angiotensin-(1-7) in ischaemic stroke Exp. Physiol. 2018 103 916 923 29663576
  39. [39]Becker LK Eccentric overload muscle damage is attenuated by a novel angiotensin- (1-7) treatment Int. J. Sports Med. 2018 39 743 748 29940668
  40. [40]Sabharwal R Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy Clin. Sci. 2014 127 101 109 24502705 PMC4318348
  41. [41]Bertagnolli M An orally active angiotensin-(1-7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats Peptides 2014 51 65 73 24262271
  42. [42]Marques FD Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats Int. J. Hypertens. 2012 2012 795452 22482038 PMC3296310
  43. [43]Marques FD An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats Hypertension 2011 57 477 483 21282558
  44. [44]Lula I Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: complete sequence-specific NMR assignments and structural studies Peptides 2007 28 2199 2210 17904691
  45. [45]Breitling S Dose-dependent, therapeutic potential of angiotensin-(1-7) for the treatment of pulmonary arterial hypertension Pulm. Circ. 2015 5 649 657 26697172 PMC4671739
  46. [46]Malek V Sharma N Sankrityayan H Gaikwad AB Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy Life Sci. 2019 221 159 167 30769114
  47. [47]Ocaranza MP Jalil JE Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling Int. J. Hypertens. 2012 2012 594361 22315665 PMC3270559
  48. [48]Cha SA Park BM Kim SH Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor Korean J. Physiol. Pharmacol. 2018 22 447 456 29962859 PMC6019878
  49. [49]Bruce E Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis Br. J. Pharmacol. 2015 172 2219 2231 25522140 PMC4403089
  50. [50]Wagenaar GT Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury Am. J. Physiol. Lung Cell. Mol. Physiol. 2013 305 L341 L351 23812633 PMC3763032
  51. [51]Hernandez Prada JA Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents Hypertension 2008 51 1312 1317 18391097
  52. [52]De Maria ML Anti-hypertensive effects of diminazene aceturate: an angiotensin- converting enzyme 2 activator in rats Protein Peptide Lett. 2016 23 9 16 26458404
  53. [53]Wiemer G Dobrucki LW Louka FR Malinski T Heitsch H AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium Hypertension 2002 40 847 852 12468568
  54. [54]Savergnini SQ Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor Hypertension 2010 56 112 120 20479330
  55. [55]Liu P Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation Kidney Int. 2018 94 114 125 29691064
  56. [56]Haber PK Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro Hypertension 2014 63 774 782 24446061 PMC4004079
  57. [57]Shenoy V Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models Am. J. Respir. Crit. Care Med. 2013 187 648 657 23370913 PMC3733435
  58. [58]Singh Y Singh K Sharma PL Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats Mol. Cell. Biochem. 2013 373 189 194 23108791
  59. [59]Ma Y AVE 0991 attenuates cardiac hypertrophy through reducing oxidative stress Biochem. Biophys. Res. Commun. 2016 474 621 625 26403967
  60. [60]Keidar S Strizevsky A Raz A Gamliel-Lazarovich A ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects Nephrol. Dial. Transplant. 2007 22 597 601 17095582
  61. [61]Ortiz-Perez JT Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study PLOS ONE 2013 8 e61695 23630610 PMC3632515
  62. [62]Soro-Paavonen A Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications J. Hypertens. 2012 30 375 383 22179088
  63. [63]Roberts MA Velkoska E Ierino FL Burrell LM Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease Nephrol. Dial. Transplant. 2013 28 2287 2294 23535224 PMC7537611
  64. [64]Khlestova GV Dynamics of renin, angiotensin II, and angiotensin (1-7) during pregnancy and predisposition to hypertension-associated complications Bull. Exp. Biol. Med. 2018 165 438 439 30123953
  65. [65]Ferrario CM Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects Am. J. Hypertens 1998 11 137 146 9524041
  66. [67]Lautner RQ Discovery and characterization of alamandine: a novel component of the renin-angiotensin system Circ. Res. 2013 112 1104 1111 23446738
  67. [68]Soltani Hekmat A Javanmardi K Kouhpayeh A Baharamali E Farjam M Differences in cardiovascular responses to alamandine in two-kidney, one clip hypertensive and normotensive rats Circ. J. 2017 81 405 412 28070059
  68. [69]Souza-Neto FP Alamandine attenuates arterial remodelling induced by transverse aortic constriction in mice Clin. Sci. 2019 133 629 643 30737255
  69. [70]Ichiki T Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor Nature 1995 377 748 750 7477267
  70. [71]Hein L Barsh GS Pratt RE Dzau VJ Kobilka BK Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice Nature 1995 377 744 747 7477266
  71. [72]Tsutsumi Y Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation J. Clin. Invest. 1999 104 925 935 10510333 PMC408562
  72. [73]Ocaranza MP Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis J. Hypertens. 2014 32 771 783 24463937
  73. [74]Ali Q Wu Y Hussain T Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats Kidney Int. 2013 84 931 939 23823602 PMC4091804
  74. [75]Li XC Widdop RE AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR Br. J. pharmacology 2004 142 821 830 PMC1575063 15197103
  75. [76]Benndorf R Boger RH Ergun S Steenpass A Wieland T Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells Circ. Res. 2003 93 438 447 12881481
  76. [77]Ocaranza MP Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension J. Hypertens. 2011 29 706 715 21330937
  77. [78]Xu X RhoA-Rho associated kinase signaling leads to renin-angiotensin system imbalance and angiotensin converting enzyme 2 has a protective role in acute pulmonary embolism Thromb. Res. 2019 176 85 94 30784777
  78. [79]Fattah C Gene therapy with angiotensin-(1-9) preserves left ventricular systolic function after myocardial infarction J. Am. Coll. Cardiol. 2016 68 2652 2666 27978950 PMC5158000
  79. [80]Flores-Munoz M Angiotensin-(1-9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor Hypertension 2012 59 300 307 22184331
  80. [81]Reddy R Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study PLOS ONE 2019 14 e0213096 30845246 PMC6405137
  81. [83]Rentzsch B Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function Hypertension 2008 52 967 973 18809792
  82. [84]Xu P Sriramula S Lazartigues E ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011 300 R804 R817 21178125 PMC3075080
  83. [85]Oudit GY Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice Cardiovasc. Res. 2007 75 29 39 17499227
  84. [86]Epelman S Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system J. Am. Coll. Cardiol. 2008 52 750 754 18718423 PMC2856943
  85. [87]Redfield MM Heart failure with preserved ejection fraction N. Engl. J. Med. 2016 375 1868 1877 27959663
  86. [88]Zhong J Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction Circulation 2010 122 717 -728 20679547
  87. [89]Oliveira AC Genetic deletion of the alamandine receptor MRGD leads to dilated cardiomyopathy in mice Am. J. Physiol. Heart Circ. Physiol. 2019 316 H123 H133 30339496
  88. [90]Gao J Zucker IH Gao L Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure Am. J. Hypertens. 2014 27 1248 1256 24687998 PMC4229732
  89. [91]Burrell LM Myocardial infarction increases ACE2 expression in rat and humans Eur. Heart J. 2005 26 369 375 15671045
  90. [92]Kassiri Z Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction Circ. Heart Fail. 2009 2 446 455 19808375
  91. [93]Der Sarkissian S Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology Hypertension 2008 51 712 718 18250366
  92. [94]Santos RA Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats Physiol. Genomics 2004 17 292 299 15039487
  93. [95]Oishi Y Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling Hypertension 2003 41 814 818 12624001
  94. [96]Brede M Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice Hypertension 2003 42 1177 1182 14581297
  95. [97]Adachi Y Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice Circulation 2003 107 2406 2408 12732609
  96. [98]Yang Z Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction Circulation 2002 106 106 111 12093778
  97. [99]Qi Y Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury Exp. Physiol. 2012 97 89 101 21967903 PMC3619662
  98. [100]Lauer D Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor beta1 in the rat heart Hypertension 2014 63 e60 e67 24379181
  99. [101]Ruparelia N Chai JT Fisher EA Choudhury RP Inflammatory processes in cardiovascular disease: a route to targeted therapies Nat. Rev. Cardiol. 2017 14 133 144 27905474 PMC5525550
  100. [102]Shirazi LF Bissett J Romeo F Mehta JL Role of inflammation in heart failure Curr. Atheroscler. Rep. 2017 19 27 28432635
  101. [103]Golia E Inflammation and cardiovascular disease: from pathogenesis to therapeutic target Curr. Atheroscler. Rep. 2014 16 435 25037581
  102. [104]Guzik TJ Touyz RM Oxidative stress, inflammation, and vascular aging in hypertension Hypertension 2017 70 660 667 28784646
  103. [105]McMaster WG Kirabo A Madhur MS Harrison DG Inflammation, immunity, and hypertensive end-organ damage Circ. Res. 2015 116 1022 1033 25767287 PMC4535695
  104. [106]Hoch NE Regulation of T-cell function by endogenously produced angiotensin II Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009 296 R208 R216 19073907 PMC2643984
  105. [107]Jurewicz M Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation J. Am. Soc. Nephrol. 2007 18 1093 1102 17329576
  106. [108]Dinh QN Drummond GR Sobey CG Chrissobolis S Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension Biomed. Res. Int. 2014 2014 406960 25136585 PMC4124649
  107. [109]Rutkowska-Zapala M Human monocyte subsets exhibit divergent angiotensin I-converting activity Clin. Exp. Immunol. 2015 181 126 132 25707554 PMC4469162
  108. [110]da Silveira KD Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis J. Immunol. 2010 185 5569 5576 20935211
  109. [111]Oliveira-Lima OC Mas receptor deficiency exacerbates lipopolysaccharide-induced cerebral and systemic inflammation in mice Immunobiology 2015 220 1311 1321 26297425
  110. [112]Passos-Silva DG Verano-Braga T Santos RA Angiotensin-(1-7): beyond the cardio-renal actions Clin. Sci. 2013 124 443 456 23249272
  111. [113]Magalhaes GS Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation Br. J. Pharmacol. 2015 172 2330 2342 25559763 PMC4403097
  112. [114]Jawien J Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice J. Physiol. Pharmacol. 2012 63 77 85 22460464
  113. [115]Tesanovic S Vinh A Gaspari TA Casley D Widdop RE Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice Arterioscler. Thromb. Vasc. Biol. 2010 30 1606 1613 20448208
  114. [116]Magalhaes GS Angiotensin-(1-7) promotes resolution of eosinophilic inflammation in an experimental model of asthma Front. Immunol. 2018 9 58 29434591 PMC5797293
  115. [117]Dhande I Ma W Hussain T Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production Hypertens. Res. 2015 38 21 29 25209104 PMC4898267
  116. [118]Dhande I Ali Q Hussain T Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats Hypertension 2013 61 1218 1226 23547236 PMC3709839
  117. [119]Kaschina E Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008 118 2523 2532 19029468
  118. [120]Gonzalez L Angiotensin-(1-9) reduces cardiovascular and renal inflammation in experimental renin-independent hypertension Biochem. Pharmacol. 2018 156 357 370 30179588
  119. [134]Basu R Roles of angiotensin peptides and recombinant human ACE2 in heart failure J. Am. Coll. Cardiol. 2017 69 805 819 28209222
  120. [135]Ocaranza MP Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro J. Hypertens. 2010 28 1054 1064 20411619
  121. [136]Kluskens LD Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog J. Pharmacol. Exp. Ther. 2009 328 849 854 19038778
  122. [137]Pandey A Gaikwad AB AT2 receptor agonist compound 21: a silver lining for diabetic nephropathy Eur. J. Pharmacol. 2017 815 251 257 28943106
  123. [138]Wan Y Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist J. Med. Chem. 2004 47 5995 6008 15537354
  124. [139]Kalra S Kalra B Agrawal N Combination therapy in hypertension: an update Diabetol. Metab. Syndr. 2010 2 44 20576135 PMC2901246
  125. [140]Gradman AH Basile JN Carter BL Bakris GL & American Society of Hypertension Writing Group. Combination therapy in hypertension J. Am. Soc. Hypertension 2010 4 42 50 20374950
  126. [141]Gebreyohannes EA Bhagavathula AS Abebe TB Tefera YG Abegaz TM Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital Clin. Hypertens. 2019 25 1 30675379 PMC6332692
  127. [142]Vrijens B Vincze G Kristanto P Urquhart J Burnier M Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories BMJ 2008 336 1114 1117 18480115 PMC2386633
  128. [143]Burnier M Egan BM Adherence in hypertension Circ. Res. 2019 124 1124 1140 30920917
  129. [144]Grobe JL Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7) Am. J. Physiol. Heart Circ. Physiol. 2007 292 H736 H742 17098828
  130. [145]Machado-Silva A Passos-Silva D Santos RA Sinisterra RD Therapeutic uses for angiotensin-(1-7) Expert Opin. Ther. Pat. 2016 26 669 678 27121991
  131. [146]Yang J Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice Atherosclerosis 2015 240 544 549 25957120
  132. [147]Young D Waitches G Birchmeier C Fasano O Wigler M Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains Cell 1986 45 711 719 3708691
  133. [148]Johnson H Drummer OH Hydrolysis of angiotensin I by peptidases in homogenates of rat lung and aorta Biochem. Pharmacol. 1988 37 1131 1136 3355587
  134. [149]Santos RA Converting enzyme activity and angiotensin metabolism in the dog brainstem Hypertension 1988 11 I153 I157 2831145
  135. [150]Campagnole-Santos MJ Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats Am. J. Physiol. 1989 257 H324 H329 2750946
  136. [151]Tipnis SR A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase J. Biol. Chem. 2000 275 33238 33243 10924499
  137. [152]Donoghue M A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 Circulation Res. 2000 87 E1 E9 10969042
  138. [153]Ferreira AJ Santos RA Almeida AP Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion Hypertension 2001 38 665 668 11566952
  139. [155]Liu C Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats Amino Acids 2018 50 1071 1081 29752563 PMC6060955
  140. [156]Park BM Phuong HTA Yu L Kim SH Alamandine protects the heart against reperfusion injury via the MrgD receptor Circ. J. 2018 82 2584 2593 29998915
  141. [157]Danser AH Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis Hypertension 1994 24 37 48 8021006
  142. [158]Lawrence AC Evin G Kladis A Campbell DJ An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma J. Hypertens. 1990 8 715 724 2170511
  143. [159]Alexiou T Angiotensinogen and angiotensin-converting enzyme gene copy number and angiotensin and bradykinin peptide levels in mice J. Hypertens. 2005 23 945 954 15834279
  144. [160]Ocaranza MP Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat Hypertension 2006 48 572 578 16908757
  145. [161]Sharp S Poglitsch M Zilla P Davies NH Sturrock ED Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats J. Renin Angiotensin Aldosterone Syst. 2015 16 1149 1158 25757657
  146. [162]Haschke M Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects Clin. Pharmacokinet. 2013 52 783 792 23681967
  147. [163]Chappell MC Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am. J. Physiol. Heart Circ. Physiol. 2016 310 H137 H152 26475588 PMC4796631
  148. [164]Lortie M Bark S Blantz R Hook V Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry Anal. Biochem. 2009 394 164 170 19615967 PMC2745394
  149. [165]Aguilera G Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat Mol. Cell. Endocrinol. 1992 90 53 60 1338730
  150. [166]Qadri F Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus J. Pharmacol. Exp. Ther. 1993 267 567 574 8246129
  151. [167]Huang BS Chen A Ahmad M Wang HW Leenen FH Mineralocorticoid and AT1 receptors in the paraventricular nucleus contribute to sympathetic hyperactivity and cardiac dysfunction in rats post myocardial infarct J. Physiol. 2014 592 3273 3286 24951624 PMC4146375
  152. [168]Iyer SN Lu D Katovich MJ Raizada MK Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense Proc. Natl Acad. Sci. USA 1996 93 9960 9965 8790439 PMC38537
  153. [169]Li Q Feenstra M Pfaffendorf M Eijsman L van Zwieten PA Comparative vasoconstrictor effects of angiotensin II, III, and IV in human isolated saphenous vein J. Cardiovasc. Pharmacol. 1997 29 451 456 9156353
  154. [170]Sadoshima J Izumo S Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype Circ. Res. 1993 73 413 423 8348686
  155. [171]Schieffer B Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat Circulation 1994 89 2273 2282 8181153
  156. [172]Wolf G Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors Kidney Int. 2002 61 1986 1995 12028439
  157. [173]Viswanathan M Stromberg C Seltzer A Saavedra JM Balloon angioplasty enhances the expression of angiotensin II AT1 receptors in neointima of rat aorta J. Clin. Invest. 1992 90 1707 1712 1331171 PMC443227
  158. [174]Jara ZP Tonin overexpression in mice diminishes sympathetic autonomic modulation and alters angiotensin type 1 receptor response Front. Med. 2018 5 365 PMC6352559 30729109
  159. [175]de Queiroz TM Monteiro MM Braga VA Angiotensin-II-derived reactive oxygen species on baroreflex sensitivity during hypertension: new perspectives Front. Physiol. 2013 4 105 23717285 PMC3651964
  160. [176]Kihara M Angiotensin II inhibits interleukin-1 beta-induced nitric oxide production in cultured rat mesangial cells Kidney Int. 1999 55 1277 1283 10200991
  161. [177]van der Mark J Kline RL Altered pressure natriuresis in chronic angiotensin II hypertension in rats Am. J. Physiol. 1994 266 R739 R748 8160866
  162. [178]Park BM Cha SA Lee SH Kim SH Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats Peptides 2016 79 66 74 27038740
  163. [179]Handa RK Krebs LT Harding JW Handa SE Angiotensin IV AT4-receptor system in the rat kidney Am. J. Physiol. 1998 274 F290 F299 9486224
  164. [180]Kramar EA Krishnan R Harding JW Wright JW Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow Regul. Pept. 1998 74 185 192 9712180
  165. [181]Coleman JK Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats Peptides 1998 19 269 277 9493859
  166. [182]Qiu H Effect of berberine on PPARalpha-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV Pharm. Biol. 2017 55 227 232 27927051 PMC6130450
  167. [183]Padia SH Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats Hypertension 2008 51 460 465 18158338
  168. [184]Fontes MA Evidence that angiotensin-(1-7) plays a role in the central control of blood pressure at the ventro-lateral medulla acting through specific receptors Brain Res. 1994 665 175 180 7882013
  169. [185]Xia H Lazartigues E Angiotensin-converting enzyme 2: central regulator for cardiovascular function Curr. Hypertens. Rep. 2010 12 170 175 20424953 PMC3093757
  170. [186]Li P Chappell MC Ferrario CM Brosnihan KB Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide Hypertension 1997 29 394 400 9039133
  171. [187]DelliPizzi AM Hilchey SD Bell-Quilley CP Natriuretic action of angiotensin(1-7) Br. J. Pharmacol. 1994 111 1 3 8012686 PMC1910022
  172. [188]Garcia-Espinosa MA Shaltout HA Gallagher PE Chappell MC Diz DI In vivo expression of angiotensin-(1-7) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 rats J. Cardiovasc. Pharmacol. 2012 60 150 157 22526299 PMC3419797
  173. [189]Sakima A Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen Am. J. Physiol. Heart Circ. Physiol. 2007 292 H1412 H1419 17085537
  174. [190]Soares ER Barbosa CM Campagnole-Santos MJ Santos RAS Alzamora AC Hypotensive effect induced by microinjection of alamandine, a derivative of angiotensin-(1-7), into caudal ventrolateral medulla of 2K1C hypertensive rats Peptides 2017 96 67 75 28889964
  175. [191]AbdAlla S Lother H Abdel-tawab AM Quitterer U The angiotensin II AT2 receptor is an AT1 receptor antagonist J. Biol. Chem. 2001 276 39721 39726 11507095
  176. [192]Bedecs K Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase Biochem. J. 1997 325 449 454 9230127 PMC1218581
  177. [193]Horiuchi M Akishita M Dzau VJ Molecular and cellular mechanism of angiotensin II-mediated apoptosis Endocr. Res. 1998 24 307 314 9888502
  178. [194]Senbonmatsu T A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy EMBO J. 2003 22 6471 6482 14657020 PMC291832
  179. [195]Gao S Angiotensin AT2 receptor agonist stimulates high stretch induced- ANP secretion via PI3K/NO/sGC/PKG/pathway Peptides 2013 47 36 44 23791669
  180. [196]Cha SA Park BM Gao S Kim SH Stimulation of ANP by angiotensin-(1-9) via the angiotensin type 2 receptor Life Sci. 2013 93 934 940 24177599
  181. [197]Abadir PM Periasamy A Carey RM Siragy HM Angiotensin II type 2 receptor-bradykinin B2 receptor functional heterodimerization Hypertension 2006 48 316 322 16754789
  182. [198]Tao X Angiotensin-(1-7) attenuates angiotensin II-induced signalling associated with activation of a tyrosine phosphatase in Sprague-Dawley rats cardiac fibroblasts Biol. Cell. 2014 106 182 192 24641355
  183. [199]McCollum LT Gallagher PE Tallant EA Angiotensin-(1-7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts Peptides 2012 34 380 388 22326709 PMC3326596
  184. [200]Shah A Angiotensin-(1-7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger Am. J. Physiol. Heart Circ. Physiol. 2010 298 H1365 H1374 20190099
  185. [201]Wang LP Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1/2 pathway Pflug. Arch. 2016 468 2041 2051 27592222
  186. [202]Carver KA Smith TL Gallagher PE Tallant EA Angiotensin-(1-7) prevents angiotensin II-induced fibrosis in cremaster microvessels Microcirculation 2015 22 19 27 25079175
  187. [203]Gomes ER Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway Hypertension 2010 55 153 160 19996065

Cited by

Sorted by citations

Authors
Paz Ocaranza, M., Riquelme, J. A., García, L., Jalil, J. E., Chiong, M., Santos, R. A. S., & Lavandero, S.
Affiliations
  • Advanced Center for Chronic Diseases (CL)
  • Pontificia Universidad Católica de Chile (CL)
  • Universidade Federal de Minas Gerais (BR)
Corresponding author
Lavandero, Sergio
ORCID
Venue
Nature Reviews Cardiology
Publisher
Springer Science and Business Media LLC
Published
2019-08-19
Volume
17
Issue
2
Pages
116-129
ISSN
  • 1759-5002 (ISSN-L)
  • 1759-5010
DOI
10.1038/s41569-019-0244-8
PMC
PMC7097090
OpenAlex
W2969292601
Cited by
561
References
2
Citations by year
2026: 37 · 2025: 51 · 2024: 88 · 2023: 99 · 2022: 87 · 2021: 116 · 2020: 81
FWCI
12.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Cardiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Universidad de Chile (submittedVersion, cc-by-nc-nd)
Funders
  • Bayer
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Comisión Nacional de Investigación Científica y Tecnológica (FONDAP #15130011, 11181000, 15130011)
  • Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias (15130011)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
  • Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
renin-angiotensin system, angiotensin-(1-7), angiotensin-(1-9), angiotensin-converting enzyme 2, angiotensin II type 2 receptor, Mas receptor, cardiovascular disease, therapeutic target
MeSH terms
Proto-Oncogene Mas, Animals, Cardiovascular Agents, Cardiovascular Diseases, Cardiovascular System, Humans, Renin-Angiotensin System, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review